Developer of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG). The company was founded in 2016 and headquartered in Seoul, South Korea. It has raised $45.2M in series b funding, with backing from Orbit Partners, bric-investment.com, NH Investment & Securities, HB Investment, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Immunotherapy, Life Sciences - Oncology space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Diversified and Genomics - Genomics Research - Biomarker Discovery.
← All startups
Wellmarker Bio
Series BDeveloper of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG). The company was founded in…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Genomics Research > Biomarker Discovery
Institutional investors
Orbit Partnersbric-investment.comNH Investment & SecuritiesHB InvestmentCytogenMirae Asset VentureKorean Development BankGaia VenturesKB SecuritiesMagellan Technology InvestmentWeed Win InvestmentIBK CapitalThe Wells InvestmentMeritz SecuritiesYozma Group Korea
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.